Ad chides Gilead "greed" over Sovaldi pricing

Share this article:

The AIDS Healthcare Foundation (AHF) took out an ad in today's Wall Street Journal blasting Gilead and “our state and federal leaders,” whom the coalition charges with “breaking the bank by paying whatever Gilead and its pharma allies demand without question.”

The half-page, four-color ad was slated to run in WSJ editions in Northern California and the Washington/Maryland/Virginia markets, AHF said, coinciding with Gilead's Annual General Meeting in Millbrae, CA.

The headline of the ad reads:


The nonprofit AIDS organization has been a frequent critic of drug pricing and has been vocal before.

In January, the group's leader—Michael Weinstein—also referred to Gilead's HIV prevention treatment, Truvada, as a “party drug,” amid reports from the New York Times about the drug's stigma in the gay community.  

And in 2007 the group went so far as to file a suit with Pfizer over its DTC campaign for ED drug Viagra. AHF accused Pfizer of promoting recreational use of Viagra and suggested a link between the drug and illicit methamphetamine use. A Pfizer spokesperson at the time denied the claims and added that AHF had approached the company, “with a multimillion-dollar funding request for a crystal meth educational program.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.